Portrait of Claire Li

Claire Li

Counsel · Fangda Partners · Beijing

Expertise

Industries
  • Life sciences and healthcare
  • Energy and natural resources
  • Technology, media and telecom
  • Manufacturing
  • Automotive
  • Consumer and retail
  • Financial services
Matters involving
Foreign languages
  • English
  • German

Representative matters

M&A

  • Represented Sino Biopharmaceutical in its acquisition of 100% equity interests in Hygieia
  • Represented TCL CSOT in its CNY 13.703 billion acquisition of LG Display’s core LCD business in China
  • Represented TCL business units in Maxeon Solar Technologies’ global restructuring, which spanned over 30 jurisdictions and involved multiple acquisitions and divestitures
  • Represented Luxshare Precision (002475.SZ) in its CNY 1.652 billion acquisition of Qorvo’s semiconductor packaging and testing line and in its long-term strategic cooperation agreement with Qorvo
  • Represented EF in the restructuring and sale of its global EF Kids & Teens business to Permira
  • Represented KPS Capital in its EUR 3.5 billion acquisition of 100% equity interest in Siemens’ electrical motor and large-drive business Innomotics
  • Represented KPS Capital in its EUR 1.7 billion acquisition of 100% equity interest in INEOS Composites, a global leader in producing resins and gelcoats
  • Represented China Huaneng in its acquisition of multiple photovoltaic power plants from GCL
  • Represented Shanghai Electric in the acquisition of multiple photovoltaic power plants
  • Represented VNET Group in its acquisition of TenxCloud
  • Represented a Chinese company in its proposed sale of its shares in a German listed company to a world-leading automobile manufacturer

Joint Venture, Strategic Cooperation and Outbound Investment

  • Represented Alibaba in its formation of an equity joint venture with Accenture to provide SaaS solutions with a special focus on consumer goods and new retail, smart commuting, and digital energy
  • Represented Mylan N.V., as its PRC counsel, in forming a new global pharmaceutical company through its combination with Upjohn, the off-patent branded and generic medicines business of Pfizer Inc.
  • Represented a global pharmaceutical company in its proposed strategic alliance with a leading pharmaceutical group in China
  • Represented various foreign companies in forming joint ventures in China with their Chinese partners
  • Represented multiple Chinese companies in their outbound investments in Central Asia, Southeast Asia, Africa, Europe, the Middle East and other regions

Private Equity & Venture Capital

  • Represented CDH, AEP, KKR, Boyu Capital, Hillhouse Capital, CICC Capital, Guanghua Wutong, Jinyi Capital, Temasek and other private equity funds and venture capital in their investments in various portfolio companies
  • Represented Didi, Sunshine Insurance, Ping An Insurance and other companies in their equity investments in various start-up companies
  • Represented Sina, Unogen and other companies in their early-stage equity financings

Background

Professional experience

  1. 2018 –

    Fangda

  • Claire joined Fangda in 2018. Before joining the firm, she worked at a renowned law form in Frankfurt, Germany.

Education

Southwest University of Political Science and Law
LL.B.
Tsinghua University
LL.M.
University of Freiburg
Dr. iur. (Doctor of Law)

Qualifications

  • Admitted to practice in the PRC · PRC

Writing & activities

Publications

  • Die Veräußerung von GmbH-Geschäftsanteilen an Dritte: Eine rechtsvergleichende Untersuchung zwischen dem deutschen und dem chinesischen RechtLIT Verlag · 2020